A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism

A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism

Abstract Background Natural cytokines are poorly suited as therapeutics for systemic administration due to suboptimal pharmacological and pharmacokinetic (PK) properties. Recombinant human interleukin-2 (rhIL-2) has shown promise for treatment of autoimmune (AI) disorders yet exhibits short systemic...

Full description

Bibliographic Details
Main Authors: Jerod L. Ptacin, Lina Ma, Carolina E. Caffaro, Nicole V. Acuff, Kristine Germar, Peter Severy, Yanyan Qu, Jose-Luis Vela, Xinming Cai, Kristine M. San Jose, Hans R. Aerni, David B. Chen, Ean Esche, Taylor K. Ismaili, Rob Herman, Yelena Pavlova, Michael J. Pena, Jasmine Nguyen, Lilia K. Koriazova, Laura K. Shawver, Ingrid B. Joseph, Jill Mooney, Mark Peakman, Marcos E. Milla
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:Communications Medicine
Online Access:https://doi.org/10.1038/s43856-024-00485-z

Internet

https://doi.org/10.1038/s43856-024-00485-z

Similar Items